EU health regulator backs Amicus therapy for muscle disorder
2022-12-16
上市批准
Dec 16 (Reuters) - The European Union's health regulator said on Friday it had recommended granting marketing authorization for Amicus Therapeutics Inc's (FOLD.O) experimental therapy to treat Pompe disease, a muscle disorder.
Pompe disease is a rare genetic condition that leads to a buildup of the complex sugar glycogen, causing muscular impairment. The condition may also lead to heart failure in young patients.
The European Medicines Agency's decision comes amid delays for the drug in the United States.
The U.S. Food and Drug Administration (FDA) in October had extended the review of the drug for the second time, blaming the delay on pandemic-related travel restrictions that kept it from conducting a required inspection of the manufacturing site.
The EU agency's decision only applies to Amicus' lab-made protein cipaglucosidase alfa, which is used in combination with another drug called miglustat.
(This story has been corrected to say 2023, not 2022, in the last paragraph)
Our Standards: The Thomson Reuters Trust Principles.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。